Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine.

ABSTRACT:

Background

Which medication, if any, to use to prevent the headache of pediatric migraine has not been established.

Methods

We conducted a randomized, double-blind, placebo-controlled trial of amitriptyline (1 mg per kilogram of body weight per day), topiramate (2 mg per kilogram per day), and placebo in children and adolescents 8 to 17 years of age with migraine. Patients were randomly assigned in a 2:2:1 ratio to receive one of the medications or placebo. The primary outcome was a relative reduction of 50% or more in the number of headache days in the comparison of the 28-day baseline period with the last 28 days of a 24-week trial. Secondary outcomes were headache-related disability, headache days, number of trial completers, and serious adverse events that emerged during

SUBMITTER: Powers SW 

PROVIDER: S-EPMC5226887 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature